Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells - Perry, John M.; Tao, Fang; Roy, Anuradha; Lin, Tara; He, Xi C.; Chen, Shiyuan; Lu, Xiuling; Nemechek, Jacqelyn; Ruan, Linhao; Yu, Xiazhen; Dukes, Debra; Moran, Andrea; et al. (Nature cell biology, 2020)
Keywords: 1-Phosphatidylinositol 3-kinase; 13/31; 45; 45/100; 45/15; 59; 631/532/71; 631/80/86; 64; 64/60; 692/699/67/1059/2325; 692/699/67/1059/2326; AKT protein; Animals; Antibiotics, Antineoplastic - pharmacology; Apoptosis; beta Catenin - physiology; Biomedical and Life Sciences; Cancer Research; Cancer therapies; Cell Biology; Cell Proliferation; Chemotherapy; Cytotoxicity; Developmental Biology; Doxorubicin; Doxorubicin - pharmacology; Drug Resistance, Neoplasm; Female; Gene expression; High-throughput screening; Humans; Immune checkpoint; Inhibitors; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - metabolism; Leukemia, Myeloid, Acute - pathology; Life Sciences; Male; Mice; Mice, Knockout; Neoplastic Stem Cells - drug effects; Neoplastic Stem Cells - metabolism; Neoplastic Stem Cells - pathology; PD-L1 protein; Phosphatidylinositol 3-Kinases - genetics; Phosphatidylinositol 3-Kinases - metabolism; Progenitor cells; Proto-Oncogene Proteins c-akt - genetics; Proto-Oncogene Proteins c-akt - metabolism; PTEN Phosphohydrolase - physiology; Stem cell transplantation; Stem Cells; Tumor Cells, Cultured; Tumorigenesis; Wnt protein; Wnt Proteins - physiology; Xenograft Model Antitumor Assays; β-Catenin